Company Prometheus Biosciences, Inc.

Equities

RXDX

US74349U1088

Biotechnology & Medical Research

Business description: Prometheus Biosciences, Inc.

Sales by Activity: Prometheus Biosciences, Inc.

Geographical breakdown of sales: Prometheus Biosciences, Inc.

Executive Committee: Prometheus Biosciences, Inc.

Composition of the Board of Directors: Prometheus Biosciences, Inc.

Company details: Prometheus Biosciences, Inc.

Other Biotechnology & Medical Research

Sector

Inactive Instrument

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.

Number of employees: 97

Fiscal Period: December	2018	2019	2020	2021	2022
Therapeutics	-	1.12M	1.23M	3.13M	6.81M
Diagnostic Services	-	22.67M	-	-	-

See all business segments

Fiscal Period: December	2018	2019	2020	2021	2022
United States	-	23.79M	1.23M	3.13M	6.81M

See all geographic segments

Manager	Title	Age	Since
Rita Karachun CEO	Chief Executive Officer	61	2023-06-15
Olivier Laurent CTO	Chief Tech/Sci/R&D Officer	53	2020-08-31
Allison Luo CTO	Chief Tech/Sci/R&D Officer	51	2018-07-31
Vika Brough PRN	Corporate Officer/Principal	-	-
Christropher Doughty PRN	Corporate Officer/Principal	38	2021-01-31

See PROMETHEUS BIOSCIENCES, INC. governance

Director	Title	Age	Since
Rita Karachun BRD	Director/Board Member	61	2023-06-15
Jon Filderman BRD	Director/Board Member	-	2023-06-15
Aaron Rosenberg BRD	Director/Board Member	49	2023-06-15

Composition of the Board of Directors

Prometheus Biosciences, Inc.

126 East Lincoln Avenue

07065, Rahway

https://www.precisionibd.com/

address Prometheus Biosciences, Inc.(RXDX)

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LONZA GROUP AG	-1.79%	-5.23%	-6.09%	+11.09%	45.43B
IQVIA HOLDINGS INC.	-1.65%	-1.59%	+10.92%	+4.28%	37.85B
BEONE MEDICINES AG	-0.55%	-1.19%	+76.99%	+56.17%	35.31B
CELLTRION, INC.	+0.05%	+1.91%	+10.32%	+20.20%	27.66B
MEDPACE HOLDINGS, INC.	-1.46%	+1.78%	+60.58%	+164.03%	15.72B
REVOLUTION MEDICINES, INC.	+0.52%	-0.90%	+75.65%	+231.60%	15.26B
ICON PUBLIC LIMITED COMPANY	-1.76%	+0.38%	-11.49%	-5.32%	14.25B
TEMPUS AI, INC.	-4.40%	-7.89%	+68.16%	-	12.56B
ASCENDIS PHARMA A/S	+4.88%	+7.29%	+68.72%	+79.89%	13.47B
Average	-0.43%	-0.83%	+39.31%	+70.24%	24.17B
Weighted average by Cap.	-0.75%	-1.50%	+31.56%	+50.35%

See all sector performances

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research